In comparison to controls and monotherapy, H&E staining of tumor sections revealed enhanced immune infiltrates with reduced tumor burden in the anti-PD-1 plus CCL21-DC tumor lysate vaccine treatment group (Figure 2A). This evidence concerns the gene CCL21 and neoplasm.